MedPath

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

Phase 3
Completed
Conditions
Type 2 Diabetes
Interventions
Registration Number
NCT00918138
Lead Sponsor
AstraZeneca
Brief Summary

The purpose of this study was to compare effect of Saxagliptin as add-on to Metformin on 24-hour mean weighted glucose (MWG) to the effect of uptitrating Metformin in subjects with T2DM inadequately controlled on metformin alone.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
219
Inclusion Criteria
  • Type 2 diabetes
  • 18-78 years of age
  • Taking stable dose of metformin immediate release (IR) or XR ≥850 mg and ≤1500 mg as monotherapy for at least 8 weeks prior to screening
  • Glycosylated hemoglobin A1C (A1C) 7.5-11.5% at screening
  • Fasting C-peptide: ≥1.0 ng/mL
  • FPG≥126 mg/dl obtained at the Day -7 visit
  • Body mass index (BMI): ≤ 40kg/m²
  • A1C ≥ 7.0% and ≤ 11.0% obtained at the Day -7 visit for randomization
Exclusion Criteria
  • Women of childbearing potential unable or unwilling to use acceptable birth control
  • Women who are pregnant or breastfeeding
  • Significant cardiovascular history
  • Active liver disease
  • Renal impairment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Metformin XR + Metformin XR + matching Saxagliptin placeboMetformin XR(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)
Saxagliptin + Metformin XR + matching Metformin XR placeboMetformin XR(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
Metformin XR + Metformin XR + matching Saxagliptin placeboPlacebo matching Saxagliptin(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)
Saxagliptin + Metformin XR + matching Metformin XR placeboSaxagliptin(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
Saxagliptin + Metformin XR + matching Metformin XR placeboPlacebo matching Metformin XR(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
Primary Outcome Measures
NameTimeMethod
Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4Baseline, Week 4

Adjusted mean change from baseline in MWG achieved with saxagliptin 5 mg plus metformin XR versus placebo plus metformin XR at Week 24. MWG was calculated as the area under the curve (AUC) for the full 24 hours expressed as average mg/dL. Glucose measurements were collected 30 minutes before and just prior to each meal (0 minutes) and 30, 60, 120, and 180 minutes after each meal (with 1 additional measurement at 240 minutes after the evening meal), midnight, 3 AM, and at end-of-domicile visit 24 hours after the first measurement. Mean change from baseline was adjusted for baseline value.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline to Week 4 in 2-hour Postprandial Glucose (PPG) (2 Hours After the Evening Meal)Baseline, Week 4

Adjusted mean change from baseline in 2-hour postprandial (after mealtime) plasma glucose two hours after start of the evening meal during 24-hour domicile visits evaluated both at pre-randomization (baseline) and at Week 4. Mean change from baseline was adjusted for baseline value.

Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning MealBaseline, Week 4

FPG measurements were done at baseline, day 14 and 28. At baseline and day 28, the FPG value=plasma glucose value collected 30 minutes prior to the morning meal during the domicile visit.

Trial Locations

Locations (13)

Dedicated Phase I, Inc.

🇺🇸

Phoenix, Arizona, United States

Palm Springs Research Institute

🇺🇸

Hialeah, Florida, United States

River Birch Research Alliance, Llc

🇺🇸

Blue Ridge, Georgia, United States

Clinical Trials Of Texas Inc.

🇺🇸

San Antonio, Texas, United States

Advanced Clinical Research

🇺🇸

West Jordan, Utah, United States

Local Institution

🇲🇽

Durango, Mexico

Healthcare Clinical Data, Inc.

🇺🇸

North Miami, Florida, United States

Clinical Research Of South Florida

🇺🇸

Coral Gables, Florida, United States

Pacific Sleep Medicine Services (Avastra Clinical Trials)

🇺🇸

Redlands, California, United States

Orange County Research Center

🇺🇸

Tustin, California, United States

Jasper Clinic, Inc.

🇺🇸

Kalamazoo, Michigan, United States

Clinilabs, Inc.

🇺🇸

New York, New York, United States

Medpace Clinical Pharmacology Unit

🇺🇸

Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath